Overview

Dashboard News

CRISPR Therapeutics gains momentum with Medicaid plan for gene-editing treatment
CRISPR Therapeutics has faced a 23% decline in stock value this year despite recent regulatory approvals for its gene-editing medicine, Casgevy, which treats sickle cell disease and beta-thalassemia. The high cost of $2.2 million per treatment poses accessibility challenges, but a new U.S. government plan aims to help Medicaid patients afford it, potentially expanding access for many. However, the company reported only $1.6 million in revenue in the first nine months, indicating slow uptake of Casgevy.
Yahoo Finance
United States Dollar Vertex Pharmaceuticals Inc CRISPR Therapeutics AG SAU BHR GBR USA Joe Biden Show more
Healthcare, Market Report
18:25 22.12.2024
CRISPR Therapeutics gains momentum with new Medicaid plan for gene therapy access
CRISPR Therapeutics has faced a challenging market, with shares down 23% year-to-date despite recent regulatory approvals for its gene-editing medicine, Casgevy, which treats sickle cell disease and beta-thalassemia. The Biden administration's new Medicaid initiative aims to improve access to Casgevy, potentially expanding its market significantly. With a projected peak annual sales exceeding $2.2 billion, the company is well-positioned for future growth, although it currently reports minimal revenue.
The Motley Fool
United States Dollar Vertex Pharmaceuticals Inc bluebird bio, Inc. CRISPR Therapeutics AG SAU USA BHR GBR Show more
Healthcare, Market Report
18:25 22.12.2024
two healthcare dividend stocks to consider during market volatility
As 2024 closes with the S&P 500 achieving a 25% return, investors are advised to consider defensive strategies amid potential market volatility. AbbVie, with a strong dividend yield and promising drug sales growth, and Pfizer, offering a high yield and new growth drivers, are highlighted as solid healthcare sector investments for uncertain times. Both companies are well-positioned for continued success as they enter 2025.
The Motley Fool
United States Dollar ABBVIE Pfizer Inc. USA
Healthcare, Market Report
12:50 22.12.2024
Eli Lilly and Amgen benefit from Novo Nordisk's disappointing obesity data
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position and suggesting CagriSema's efficacy aligns more closely with MariTide, which may have gastrointestinal side effects.
Yahoo Finance
Novo Nordisk A/S Amgen Inc. Eli Lilly and Company DNK Trung Huynh Show more
Healthcare, Market Report
13:30 21.12.2024
Novo obesity data boosts outlook for Eli Lilly and Amgen stocks
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position in the market. The analysis suggests that CagriSema's efficacy aligns more closely with MariTide, which may present gastrointestinal issues and a less appealing monthly titration regimen.
Yahoo Finance
Amgen Inc. Novo Nordisk A/S Eli Lilly and Company DNK Trung Huynh Show more
Healthcare, Market Report
13:30 21.12.2024
quantum biopharma invests one million dollars in bitcoin and cryptocurrencies
Quantum BioPharma has invested $1 million in Bitcoin and other cryptocurrencies as part of its strategy to diversify its treasury and facilitate cryptocurrency transactions. This move aligns with a growing trend among companies adopting digital assets as a hedge against inflation, despite causing a 10% drop in its Nasdaq shares. The investment places Quantum BioPharma among several firms integrating cryptocurrencies into their financial strategies, reflecting a broader shift in the corporate landscape.
Coinchapter
Microsoft Corporation MicroStrategy Inc Amazon.com, Inc. CAN Show more
Healthcare, Market Report
23:26 20.12.2024
Intellia Therapeutics stock plummets amid disappointing therapy data and performance
Intellia Therapeutics, Inc. has seen its shares plummet 60.4% in 2024, significantly underperforming the industry and the S&P 500. Despite promising data from its CRISPR-based therapies, including the investigational nexiguran ziclumeran for ATTR amyloidosis, investor disappointment has grown due to recent trial results. The company continues to advance its innovative gene editing pipeline, with ongoing studies showing substantial serum TTR reduction in patients.
Yahoo Finance
Regeneron Pharmaceuticals, Inc. Intellia Therapeutics, Inc. USA
Healthcare, Market Report
18:57 20.12.2024
quantum biopharma invests one million in bitcoin for treasury diversification
Quantum BioPharma has invested $1 million in Bitcoin and other cryptocurrencies to diversify its treasury, joining a trend among companies seeking inflation hedges. Following the announcement, its Nasdaq shares fell nearly 10%. The firm is now positioned to conduct transactions in cryptocurrencies, reflecting a broader corporate shift towards digital assets.
Cointelegraph
JIVA Technologies Inc. Microsoft Corporation MicroStrategy Inc RumbleOn, Inc. Hoth Therapeutics, Inc. Quantum BioPharma Ltd. Amazon.com, Inc. USA DEU Show more
Healthcare, News Article
18:36 20.12.2024
growth prospects in the food for special medical purpose market
The Food for Special Medical Purpose market is poised for growth, driven by the rise in chronic illnesses and an aging population, particularly in Asia Pacific and Europe. Key players include Nestle, Danone Nutricia, and Abbott, with significant investments in R&D despite high costs and regulatory challenges. The market focuses on tailored nutritional solutions for infants, adults, and the elderly, reflecting evolving dietary needs.
openPR.com
United States Dollar Fresenius Kabi AG Targeted Medical Pharma, Inc. Danone Nutricia SL Nestlé S.A. Bayer AG Ajinomoto Co., Inc. AUT CHE JPN ESP USA DEU Nidhi Bhawsar Show more
Healthcare, Market Report
18:18 20.12.2024
novo nordisk shares plunge after disappointing weight loss drug trial results
Novo Nordisk experienced a significant drop in stock value, plummeting over 22% after clinical trial results for its weight-loss drug Cagrisema fell short of expectations, with participants losing an average of 22.7% of their weight compared to the anticipated 25%. Despite a 21% rise in net profit in the previous quarter and strong sales for its other products, the company faces increasing competition and production capacity challenges. The World Obesity Federation forecasts a growing market for weight-loss treatments, highlighting the potential for future growth amid rising obesity rates globally.
Fortune Europe
United States Dollar Novo Nordisk A/S Eli Lilly and Company DNK Martin Holst Lange Mads Krogsgaard Thomsen Show more
Healthcare, News Article
15:46 20.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Central Bank Actions Banking Regulations Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Mergers & Acquisitions Cryptocurrency & Blockchain Regulations Cryptocurrency Developments Blockchain Technology Adoption Market Analysis and Predictions Anti-Money Laundering (AML) Regulations Emerging Startups Cryptocurrency Regulations SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN CHN IND SGP DNK CAN NGA FIN COL AUT LIE TUR KOR
Companies:
Credit Suisse Real Estate Fund Siat BlackRock, Inc. Coinbase Global, Inc. Solana USD Ethereum USD Tesla, Inc. Ripples USD Fidelity Contrafund Cardano USD Apple Inc. NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Google Inc. Amazon.com, Inc. MicroStrategy Inc Tether USDt CNY End Federal Reserve USD MicroStrategy Incorporated Crypto.com Staked ETH USD
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Thomas Jordan Gary Gensler Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Sergio Ermotti Dana White Joe Biden Charles Hoskinson

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings